Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of disorders ranging from simple steatosis (non-alcoholic fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH) and cirrhosis. NAFL increases the risk of liver fibrosis. If the liver is fatty due to causes of insulin resistance such as obesity and physical inactivity, it overproduces glucose and triglycerides leading to hyperinsulinemia and a low high-density lipoprotein (HDL) cholesterol concentration. The latter features predispose to type 2 diabetes and cardiovascular disease (CVD). Understanding the impact of nutritional modulation of liver fat content and insulin resistance is therefore of interest for prevention and treatment of NAFLD. Hypocaloric, especially low carbohydrate ketogenic diets rapidly decrease liver fat content and associated metabolic abnormalities. However, any type of caloric restriction seems effective long-term. Isocaloric diets containing 16%–23% fat and 57%–65% carbohydrate lower liver fat compared to diets with 43%–55% fat and 27%–38% carbohydrate. Diets rich in saturated (SFA) as compared to monounsaturated (MUFA) or polyunsaturated (PUFA) fatty acids appear particularly harmful as they increase both liver fat and insulin resistance. Overfeeding either saturated fat or carbohydrate increases liver fat content. Vitamin E supplementation decreases liver fat content as well as fibrosis but has no effect on features of insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583 · cited 1×
“The high concentration of VLDL leads to lowering of high-density lipoprotein (HDL) cholesterol and to generation of small dense LDL particles, which are known to be highly atherogenic (see [23] for review).”
BackgroundEkstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 5×
“Given the high prevalence of both “Metabolic NAFLD”, “PNPLA3 NAFLD” and “TM6SF2 NAFLD” and the associated risks of type 2 diabetes and CVD (“Metabolic NAFLD”) and advanced liver disease (all forms increase the risk of NASH, cirrhosis and HCC), there is a need for large multicenter studies with sufficient numbers of pa…”
BackgroundInfluentialStanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Metabolic Effects of Fructose and the Worldwide Increase in Obesity
Tappy, L., & Lê, K.-A. (2010) · Physiological Reviews · doi:10.1152/physrev.00019.2009 · Cited by 1,256
Brunt, E. M., Kleiner, D. E., Wilson, L. A., Belt, P., & Neuschwander-Tetri, B. A. (2011) · Hepatology · doi:10.1002/hep.24127 · Cited by 1,251
Kozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234 · cited 6×
“Hepatic knockdown of TM6SF2 decreases very lowdensity lipopr tein (VLDL) secretion [14,16].”
BackgroundInfluentialVessby, B., Uusitupa, M., Hermansen, K., Riccardi, G., Rivellese, A. A., Tapsell, L. C., Nälsén, C., Berglund, L., Louheranta, A., Rasmussen, B. M., et al. (2001) · Diabetologia · doi:10.1007/s001250051620 · Cited by 1,119 · cited 2×
“For example, MUFAs did not affect insulin sensitivity In the “KANWU” study [49] or in the more recent large 24-week “RISCK” study where subjects were randomized to consume either a high SFA or a high MUFA diet [51].”
BackgroundResultLambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069 · cited 4×
“However, in absolute terms, lipolysis is the main source of intrahepatocellular triglycerides both in normal subjects and those with NAFLD [17].”
BackgroundInfluentialCani, P. D., Osto, M., Geurts, L., & Everard, A. (2012) · Gut Microbes · doi:10.4161/gmic.19625 · Cited by 864
Ryan, M. C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., O’Dea, K., Desmond, P. V., Johnson, N. A., & Wilson, A. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.012 · Cited by 778
Gastaldelli, A., Cusi, K., Pettiti, M., Hardies, J., Miyazaki, Y., Berria, R., Buzzigoli, E., Sironi, A. M., Cersosimo, E., Ferrannini, E., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.068 · Cited by 629 · cited 1×
“Studies using stable isotopes to trace pathways of hepatic triglyceride synthesis have shown that both adipose tissue lipolysis and DNL are increased in NAFLD [17,60–62] (Figure 1).”
BackgroundMaersk, M., Belza, A., Stødkilde-Jørgensen, H., Ringgaard, S., Chabanova, E., Thomsen, H., Pedersen, S. B., Astrup, A., & Richelsen, B. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.022533 · Cited by 603 · cited 2×
“found six months of sugar-sweetened beverage (SSB) to increase liver fat more than milk [39].”
BackgroundThoma, C., Day, C. P., & Trenell, M. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.010 · Cited by 523 · cited 2×
“NASH is not a contraindication for surgery unless complicated by cirrhosis or portal hypertension (see [42–45] for reviews).”
BackgroundEffect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis
Mummadi, R. R., Kasturi, K. S., Chennareddygari, S., & Sood, G. K. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.08.012 · Cited by 511
Bjermo, H., Iggman, D., Kullberg, J., Dahlman, I., Johansson, L., Persson, L., Berglund, J., Pulkki, K., Basu, S., Uusitupa, M., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.030114 · Cited by 490 · cited 4×
“In the largest of the isocaloric studies [27], macronutrient composition was maintained essentially unchanged but the quality of the fat differed.”
BackgroundInfluentialDietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction
Kirk, E., Reeds, D. N., Finck, B. N., Mayurranjan, M. S., Patterson, B. W., & Klein, S. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.048 · Cited by 440 · cited 6×
“For example, two to six days of a hypocaloric diet ( ́1000 cal/day) decreases liver fat by 30%–45% in the face of trivial amounts of weight loss [31,46].”
BackgroundResultInfluentialRosqvist, F., Iggman, D., Kullberg, J., Cedernaes, J., Johansson, H.-E., Larsson, A., Johansson, L., Ahlström, H., Arner, P., Dahlman, I., et al. (2014) · Diabetes · doi:10.2337/db13-1622 · Cited by 429 · cited 2×
“[35] compared a diet enriched with SFAs at the expense of PUFAs to a diet rich in PUFAs but poor in SFAs.”
BackgroundDietary fat content modifies liver fat in overweight nondiabetic subjects
Westerbacka, J., Lammi, K., Häkkinen, A.-M., Rissanen, A., Salminen, I., Aro, A., & Yki-Järvinen, H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1983 · Cited by 379 · cited 3×
“10 33 43 2 weeks C ISO 16% 61% 56% 31% 10–8 * 10–13 fS-Ins Improved Worsened 2005 [25]”
BackgroundSelf-citationMahdessian, H., Taxiarchis, A., Popov, S., Silveira, A., Franco-Cereceda, A., Hamsten, A., Eriksson, P., & van't Hooft, F. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323785111 · Cited by 369 · cited 2×
“Hepatic knockdown of TM6SF2 decreases very low-density lipoprotein (VLDL) secretion [14,16].”
BackgroundKotronen, A., Juurinen, L., Tiikkainen, M., Vehkavaara, S., & Yki–Järvinen, H. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.021 · Cited by 339 · cited 1×
“Studies using stable isotopes to trace pathways of hepatic triglyceride synthesis have shown that both adipose tissue lipolysis and DNL are increased in NAFLD [17,60–62] (Figure 1).”
BackgroundSelf-citationBrowning, J. D., Baker, J. A., Rogers, T., Davis, J., Satapati, S., & Burgess, S. C. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.007674 · Cited by 328
Haufe, S., Engeli, S., Kast, P., Böhnke, J., Utz, W., Haas, V., Hermsdorf, M., Mähler, A., Wiesner, S., Birkenfeld, A. L., et al. (2011) · Hepatology · doi:10.1002/hep.24242 · Cited by 307
Bozzetto, L., Prinster, A., Annuzzi, G., Costagliola, L., Mangione, A., Vitelli, A., Mazzarella, R., Longobardo, M., Mancini, M., Vigorito, C., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0033 · Cited by 227 · cited 6×
“Two isocaloric studies compared the effect of increasing total fat content using mainly MUFAs [28,30].”
BackgroundInfluentialJebb, S. A., Lovegrove, J. A., Griffin, B. A., Frost, G. S., Moore, C. S., Chatfield, M. D., Bluck, L. J., Williams, C. M., & Sanders, T. A. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.29096 · Cited by 192
Seppala-Lindroos, A. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3023 · Cited by 168
Self-citationSobrecases, H., Lê, K.-A., Bortolotti, M., Schneiter, P., Ith, M., Kreis, R., Boesch, C., & Tappy, L. (2010) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.03.003 · Cited by 161 · cited 5×
“High Fat Low Carb (10 = [34]) and High PUFA Low SFA vs.”
BackgroundInfluentialBravo, S., Lowndes, J., Sinnett, S., Yu, Z., & Rippe, J. (2013) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2012-0322 · Cited by 86 · cited 1×
“7 fS-Ins NS NS 2013 [40] SUCROSE 8%–30% b 14.”
Utzschneider, K. M., Bayer-Carter, J. L., Arbuckle, M. D., Tidwell, J. M., Richards, T. L., & Craft, S. (2013) · British Journal of Nutrition · doi:10.1017/s0007114512002966 · Cited by 81
Cited by
Impaired adipogenesis and dysfunctional adipose tissue in human hypertrophic obesity
Hammarstedt, A., Gogg, S., Hedjazifar, S., Nerstedt, A., & Smith, U. (2018) · Physiological Reviews · doi:10.1152/physrev.00034.2017 · Cited by 462
Luukkonen, P. K., Sädevirta, S., Zhou, Y., Kayser, B., Ali, A., Ahonen, L., Lallukka, S., Pelloux, V., Gaggini, M., Jian, C., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0071 · Cited by 428
“Limitations of our study include small sample size although the largest of its kind (35).”
BackgroundSelf-citationNonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
Dietary carbohydrates and fats in nonalcoholic fatty liver disease
Yki-Järvinen, H., Luukkonen, P. K., Hodson, L., & Moore, J. B. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00472-y · Cited by 294
Self-citationFructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism
Jegatheesan, P., & De Bandt, J. (2017) · Nutrients · doi:10.3390/nu9030230 · Cited by 280
Metadata
- Authors
- Yki-Järvinen, H.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2015-11-05
- Volume
- 7
- Issue
- 11
- Pages
- 9127-9138
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W2116724810
- Cited by
- 154
- References
- 33
- FWCI
- 12.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.